B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis

Alexander Schwarz1,2,3,4,5,6, Bettina Balint1,2,3,4,5,6, Mirjam Korporal‐Kuhnke1,2,3,4,5,6, Sven Jarius1,2,3,4,5,6, Kathrin von Engelhardt1,2,3,4,5,6, Alexandra Fürwentsches1,2,3,4,5,6, Cornelia Bußmann1,2,3,4,5,6, Friedrich Ebinger1,2,3,4,5,6, Brigitte Wildemann1,2,3,4,5,6, Jürgen Haas1,2,3,4,5,6
1Child Neurology Practice (C.B.), ATOS Clinic Heidelberg
2Department of Child and Adolescent Medicine (F.E.), St. Vincenz-Krankenhaus, Paderborn, Germany.
3Department of Pediatric Neurology (K.v.E., A.F., C.B., F.E.), University Children's Hospital, Heidelberg
4Department of Pediatrics (A.F.), University Medical Center Hamburg-Eppendorf, Hamburg
5From the Molecular Neuroimmunology Group (A.S., B.B., M.K.-K., S.J., B.W., J.H.), Department of Neurology, University Hospital of Heidelberg, Germany; Sobell Department of Motor Neuroscience and Movement Disorders (B.B.), UCL Institute of Neurology, London, UK; Department of Pediatric Neurology (K.v.E., A.F., C.B., F.E.), University Children's Hospital, Heidelberg; Department of Pediatrics (A.F.), University Medical Center Hamburg-Eppendorf, Hamburg; Child Neurology Practice (C.B.), ATOS Clinic...
6Sobell Department of Motor Neuroscience and Movement Disorders (B.B.), UCL Institute of Neurology, London, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1177/1352458511430704

10.1212/WNL.59.7.1006

10.1007/s11940-014-0336-z

10.1001/archneurol.2008.505

10.1016/S1474-4422(07)70242-9

10.1056/NEJMoa067597

10.1016/j.jaut.2011.08.003

Hauser SL, Comi GC, Hartung HP, et al. Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: results of the interferon-beta-1a-controlled, double blind, phase III OPERA I and II studies. Mult Scler 2015;21(suppl):61–62.

Montalban X, Hemmer B, Rammohan K, et al. Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis: results of the placebo-controlled, double-blind, phase III ORATORIO study. Mult Scler 2015;21(suppl):781–782.

10.1212/WNL.0000000000000125

10.1002/ana.22366

10.1177/135245859800400304

10.1212/WNL.0b013e3182a2ce0e

10.1016/j.autrev.2016.03.006

10.1002/iid3.26

10.1371/journal.pone.0083036

10.1136/ard.2010.133959

10.1002/art.10445

10.1002/ibd.22962

10.1002/art.30599

10.1038/gene.2013.18

10.1212/WNL.0b013e3181feb26f

10.1001/archneurol.2010.107

10.1016/S1474-4422(05)70071-5

10.1055/s-2007-979683

10.1016/j.autrev.2005.04.012

10.1111/j.1750-3639.2004.tb00049.x

10.1182/blood-2004-07-2507

10.1002/eji.201142108

10.1002/cyto.a.20225

10.1001/archneurol.2011.971

10.1093/brain/awh680

10.2177/jsci.38.403

10.1371/journal.pone.0002559

10.1016/j.nbd.2009.04.010

10.1212/01.WNL.0000036907.37650.8E

10.1001/archneurol.2009.135

10.1002/ana.24364

10.1016/j.jneuroim.2013.09.017